Compare Advance Auto Parts, Inc. (AAP) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Neurocrine Biosciences Inc — how do they compare? Advance Auto Parts, Inc. trades at $53.1 (market cap $3.36B), while Neurocrine Biosciences Inc trades at $159 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 5× Advance Auto Parts, Inc.'s market cap, and Advance Auto Parts, Inc. pays a 1.79% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| AAP | NBIX | |
|---|---|---|
Market Cap | $3.36B | $16.76B |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $185.50 |
52-Week Low | $38.75 | $123.10 |
Enterprise Value | $5.63B | $16.78B |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $57.80, down 0.21% on the day, with a bullish technical signal and key support at $57. The company shows mixed fundamentals: a low P/S of 0.41 and strong recent earnings beats, but thin net margins of 0.51% and negative operating cash flow in 2025. News highlights restructuring efforts and AI-driven delivery initiatives as potential growth catalysts.
The outlook is cautiously optimistic; analyst consensus targets $61.30 with a buy rating, but high debt and competitive pressures pose risks. Earnings momentum and valuation appeal offer upside, yet execution on turnaround plans is critical for sustained recovery.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
